cGMP SpCas9 is a highly purified, recombinant RNA-guided endonuclease derived from Streptococcus pyogenes, manufactured under strict Good Manufacturing Practice (GMP) quality standards. Designed exclusively for advanced in vitro assays and preclinical genome-editing research, this enzyme enables precise site-specific double-strand break (DSB) induction when complexed with target-specific guide RNAs. PX1 Research supplies cGMP-grade SpCas9 with lot-specific analytical documentation to ensure reproducible target cleavage across demanding experimental workflows.
cGMP SpCas9 is a highly purified, recombinant RNA-guided endonuclease derived from Streptococcus pyogenes, manufactured under strict Good Manufacturing Practice (GMP) quality standards. Designed exclusively for advanced in vitro assays and preclinical genome-editing research, this enzyme enables precise site-specific double-strand break (DSB) induction when complexed with target-specific guide RNAs. PX1 Research supplies cGMP-grade SpCas9 with lot-specific analytical documentation to ensure reproducible target cleavage across demanding experimental workflows.
cGMP SpCas9 refers to the recombinant *Streptococcus pyogenes* Cas9 protein produced under Current Good Manufacturing Practice (cGMP) guidelines to meet stringent purity, batch consistency, and quality control benchmarks required for rigorous scientific evaluation. As an RNA-guided DNA endonuclease, SpCas9 forms a ribonucleoprotein (RNP) complex with a single guide RNA (sgRNA) or a crRNA:tracrRNA duplex. This complex scans double-stranded target DNA for a specific protospacer adjacent motif (PAM) sequence—typically 5'-NGG-3'—and generates a blunt double-strand break three nucleotides upstream of the PAM site.
While standard laboratory reagents suffice for early-phase exploratory research, transition to cGMP-manufactured reagents minimizes lot-to-lot variability, residual host-cell proteins (HCP), and nucleic acid impurities. Supplied exclusively as a research compound for in vitro and laboratory investigation, cGMP SpCas9 provided by PX1 Research guarantees the high enzymatic specific activity and low endotoxin burdens necessary for sensitive cell culture assays and target validation protocols. Researchers can explore our complete research peptides catalog to identify complementary reagents for molecular biology applications.
The molecular architecture of SpCas9 consists of two distinct structural lobes: the recognition (REC) lobe and the nuclease (NUC) lobe. The REC lobe is responsible for binding the guide RNA scaffold and the target DNA strand, whereas the NUC lobe contains two catalytically active domains—RuvC and HNH. Preclinical structural studies demonstrate that the HNH domain cleaves the target DNA strand complementary to the guide sequence, while the RuvC domain cleaves the non-complementary strand.
Upon target identification via base-pairing between the guide RNA seed region and the protospacer, SpCas9 undergoes a conformational transition. This conformational change positions the dual catalytic centers relative to the phosphodiester backbone of the target DNA. In vitro kinetics data show that RNP complex formation dramatically increases protein stability and protects the endonuclease against premature degradation during incubation in experimental buffer systems. Detailed structural breakdowns and kinetic datasets are accessible through the PX1 research library.
The designation of cGMP signifies that the manufacturing process adheres to rigid quality management systems that govern material traceability, equipment calibration, environmental monitoring, and analytical testing protocols. For recombinant proteins like SpCas9, cGMP compliance ensures that expression systems (typically *Escherichia coli*) undergo standardized induction, harvesting, and multi-step chromatographic purification sequences.
PX1 Research ensures that every batch of cGMP SpCas9 is produced in GMP-compliant, USA-based facilities. Downstream processing incorporates hydrophobic interaction, ion exchange, and size-exclusion chromatography (SEC) to remove trace aggregates, truncated fragments, host cell genomic DNA, and residual bacterial endotoxins. Researchers requiring specialized supply agreements for bulk assay screening can evaluate our lab account authorization program to secure lot-reserved inventory.
In cell-free and cell-based laboratory models, delivering SpCas9 as a pre-assembled RNP complex offers several distinct advantages over plasmid- or mRNA-encoded delivery vectors. In vitro data indicate that RNP complexes initiate target cleavage immediately upon introduction into the target environment, followed by rapid clearing via endogenous proteolysis. This transient action window reduces the probability of off-target cleavage events without compromising on-target efficiency.
To assemble functional RNP complexes for benchtop experiments, cGMP SpCas9 is combined with synthetic guide RNA at a optimized molar ratio (typically 1:1 to 1:3 protein-to-gRNA) in a sterile, isotonic reaction buffer containing divalent cations such as Mg²⁺. Incubating the mixture at room temperature for 10 to 15 minutes allows complete assembly. Quantitative restriction digests of linearized plasmid targets demonstrate that high-purity SpCas9 achieves over 90% cleavage efficiency under controlled laboratory conditions. For broader context on endonuclease selection, review our guide on CRISPR-Cas9 endonuclease mechanisms.
Endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative expression hosts—pose a substantial confounding variable in cell culture research. Excess endotoxin levels induce non-specific inflammatory signaling, alter gene expression profiles, and diminish cell viability in primary stem cells, T-lymphocytes, and induced pluripotent stem cells (iPSCs).
PX1 Research subjects every lot of cGMP SpCas9 to rigorous chromogenic Limulus Amebocyte Lysate (LAL) or recombinant Factor C assays. By ensuring endotoxin levels remain below strictly defined thresholds (typically < 0.1 EU/µg of protein), researchers can conduct transfections and electroporation assays without triggering unwanted cellular activation or immune pathway signaling. This makes our SpCas9 recombinant protein ideal for sensitive preclinical models.
When designing target cleavage experiments, investigators must evaluate the relative parameters of different CRISPR enzymes. Standard SpCas9 recombinant protein relies on a 5'-NGG-3' PAM site and generates blunt cuts. In comparison, FnCas12a nucleases recognize a T-rich PAM (5'-TTTV-3') and produce staggered 5' overhangs, which may alter downstream repair pathway dynamics. Additionally, non-cleaving mutants such as catalytically inactive dCas9 variants allow sequence-specific DNA binding for transcriptional modulation or chromatin imaging without inducing structural strand breaks.
The table below highlights key biochemical differences across common RNA-guided research nucleases evaluated in published literature:
Maintaining the enzymatic activity of cGMP SpCas9 requires strict adherence to physical handling guidelines. Recombinant SpCas9 is typically supplied in a formulation buffer containing 20 mM HEPES (pH 7.5), 300 to 500 mM NaCl, 1 mM DTT, and 50% (v/v) glycerol for liquid storage at -20°C, or as a lyophilized cake requiring controlled reconstitution.
For lyophilized presentations, reconstitute the enzyme using sterile, nuclease-free water or provided reconstitution buffer to achieve the desired stock concentration (typically 10 to 40 µM). Gently pipet the solution to dissolve the protein; avoid vigorous vortexing, which introduces air bubbles and promotes surface-induced denaturation. Aliquot the reconstituted protein into single-use tubes to minimize freeze-thaw cycles, which cause structural aggregation and loss of cleavage kinetics. Store long-term stock solutions at -80°C.
Quality assurance at PX1 Research is grounded in objective, transparent analytical data. Every lot of cGMP SpCas9 undergoes dual verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS) performed by independent, ISO 17025-accredited testing facilities.
RP-HPLC analysis verifies molecular purity exceeding 95%, confirming the absence of low-molecular-weight degradation products or residual bacterial proteins. ESI-MS confirms exact theoretical molecular weight, verifying proper amino acid chain integrity without unintended post-translational modifications or truncation. A lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectra, endotoxin measurements, and bioburden assays is made directly accessible to verifying laboratories.
cGMP SpCas9 serves as a key reagent in preclinical target discovery, viral vector construction, cellular model engineering, and high-throughput functional genomics screening. In vitro models utilizing high-fidelity RNP complexes demonstrate minimal off-target cleavage across genomic loci while preserving target site editing frequencies.
PX1 Research is dedicated to facilitating seamless laboratory procurement. All reagents are manufactured in the USA and dispatched directly from our regional fulfillment centers in California and Arizona. Orders placed Monday through Friday before 1:00 PM PST feature same-day shipping, ensuring rapid delivery of temperature-sensitive enzymes to your facility. Institutional buyers requiring scaled quantities or standardized batch reservations can submit inquiries through our wholesale procurement portal.
What is cGMP SpCas9 and how is it used in research?
cGMP SpCas9 is a recombinant Streptococcus pyogenes Cas9 endonuclease produced under Current Good Manufacturing Practice guidelines. It is used as a research reagent in laboratory assays to introduce targeted double-strand breaks in DNA when complexed with guide RNA.
How does cGMP-grade SpCas9 differ from standard research-grade Cas9?
cGMP-grade SpCas9 undergoes more rigorous quality control, extensive purification, full lot traceability, and strict endotoxin and host-cell protein testing compared to standard research reagents, ensuring superior lot-to-lot consistency in sensitive cellular assays.
What analytical documentation accompanies PX1 Research cGMP SpCas9?
Every lot includes a comprehensive Certificate of Analysis (COA) with RP-HPLC purity profiles, mass spectrometry molecular weight verification, LAL endotoxin testing results, and sterility analysis conducted by an independent ISO 17025 lab.
What is the validated endotoxin limit for cGMP SpCas9?
PX1 Research cGMP SpCas9 is tested to ensure endotoxin levels remain below 0.1 EU/µg, minimizing non-specific cellular stress and immune pathway activation in transfected cell lines.
How should cGMP SpCas9 RNP complexes be prepared for in vitro assays?
RNP complexes are typically formed by combining SpCas9 enzyme with synthetic sgRNA at a 1:1 to 1:3 molar ratio in a sterile reaction buffer (e.g., 20 mM HEPES, 150 mM KCl, 10 mM MgCl2, pH 7.5) and incubating at room temperature for 10–15 minutes.
What are the recommended storage conditions for cGMP SpCas9?
Liquid formulations in glycerol buffer should be stored at -20°C. Reconstituted or freeze-thawed aliquots should be stored at -80°C in single-use volumes to avoid repeated freeze-thaw cycles.
Is cGMP SpCas9 suitable for human clinical administration?
No. All products supplied by PX1 Research, including cGMP SpCas9, are intended strictly for in vitro laboratory research and preclinical investigation. They are not cleared for human clinical, therapeutic, or diagnostic use.
Where is PX1 Research cGMP SpCas9 manufactured and shipped from?
PX1 Research products are manufactured in GMP-compliant facilities within the USA and shipped directly from our warehouse hubs in California and Arizona with same-day dispatch for orders placed before 1:00 PM PST M–F.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.